ArticleBMJ open2023
Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006-2019: a registry-based cohort study.
Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease.BMC cardiovascular disorders · 2026Trial
- Impact of a pharmacist adherence intervention on medication beliefs and drug-related problems in coronary patients - a process evaluation of the MIMeRiC trial.BMC health services research · 2026Article
- Outpatients' cardiac rehabilitation: the long-term experience of the Niguarda Hospital.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Poor long-term cardiovascular risk factor management after acute coronary syndrome: An observational cohort study.Journal of internal medicine · 2026Observational
- Evolving kidney disease phenotypes in type 2 diabetes: declining albuminuria and increasing isolated low eGFR.Clinical kidney journal · 2026Article
- Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice.Current atherosclerosis reports · 2026Review
- Adherence trajectories of oral lipid-lowering therapy in patients with myocardial infarction and its estimated impact on low-density lipoprotein levels.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Carotid Plaques Show More Unstable Characteristics Between 2010 and 2021 After a Prior Decade of Stabilization.Journal of the American Heart Association · 2025Article
- Article
- Article
- Causes of death and trends in mortality from the year 2000 to 2017 in patients with acute myocardial infarction.Annals of medicine · 2024Article
- Cardiac rehabilitation registries around the globe: current status and future needs.European journal of preventive cardiology · 2024Article
- Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry.European heart journal · 2024Article
- Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease.Cardiovascular diabetology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRegistries have been highlighted as means to improve quality of care. Here, we describe temporal trends in risk factors, lifestyle and preventive medication for patients after myocardial infarction (MI) registered in the quality registry Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).
designA registry-based cohort study.
settingAll coronary care units and cardiac rehabilitation (CR) centres in Sweden.
participantsPatients attending a CR visit at 1-year post-MI 2006-2019 were included (n=81 363, 18-74 years, 74.7% men). OUTCOME MEASURES: Outcome measures at 1-year follow-up included blood pressure (BP) <140/90 mm Hg, low-density lipoprotein-cholesterol (LDL-C)<1.8 mmol/L, persistent smoking, overweight/obesity, central obesity, diabetes prevalence, inadequate physical activity, and prescription of secondary preventive medication. Descriptive statistics and testing for trends were applied.
resultsThe proportion of patients attaining the targets for BP<140/90 mmHg increased from 65.2% (2006) to 86.0% (2019), and LDL-C<1.8 mmol/L from 29.8% (2006) to 66.9% (2019, p<0.0001 both). While smoking at the time of MI decreased (32.0% to 26.5%, p<0.0001), persistent smoking at 1 year was unchanged (42.8% to 43.2%, p=0.672) as was the prevalence of overweight/obesity (71.9% to 72.9%, p=0.559). Central obesity (50.5% to 57.0%), diabetes (18.2% to 27.2%) and patients reporting inadequate levels of physical activity (57.0% to 61.5%) increased (p<0.0001 for all). From 2007, >90.0% of patients were prescribed statins and approximately 98% antiplatelet and/or anticoagulant therapy. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker prescription increased from 68.7% (2006) to 80.2% (2019, p<0.0001).
conclusionsWhile little change was observed for persistent smoking and overweight/obesity, large improvements were observed for LDL-C and BP target achievements and prescription of preventive medication for Swedish patients after MI 2006-2019. Compared with published results from patients with coronary artery disease in Europe during the same period, these improvements were considerably larger. Continuous auditing and open comparisons of CR outcomes might possibly explain some of the observed improvements and differences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.